Deamorphization of spray-dried formulations via spray-blending
US-2015374623-A1 · Dec 31, 2015 · US
Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
US2016101097A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016101097-A1 |
| Application number | US-201514973778-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 18, 2015 |
| Priority date | May 18, 2004 |
| Publication date | Apr 14, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A medicament comprising, separately or together (A) glycopyrrolate; and (B) either a compound of formula I in free or salt or solvate form, wherein W, R x , R y , R 1 , R 2 , R 3 , R 4 , R 5 , R 8 and R 7 have the meanings as indicated in the specification, or a compound of formula II in free or salt or solvate form, wherein X has the meaning as indicated in the specification, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain (A) and (B) are also described.
First claim
Opening claim text (preview).
1 . A pharmaceutical composition comprising: (A) glycopyrrolate; (B) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one in free or salt form; and (C) a pharmaceutically acceptable carrier. 2 . A composition according to claim 1 wherein (A) is a racemate. 3 . A composition according to claim 2 wherein (A) is a racemate of (3S,2′R)-3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide and (2S,3′R)-3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 4 . A composition according to claim 1 , wherein (B) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one maleate. 5 . A composition according to claim 1 , wherein (B) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one acetate. 6 . A composition according to claim 1 , wherein the molar ratio of (A) to (B) is from 5:1 to 1:10. 7 . A composition according to claim 6 , wherein the molar ratio of (A) to (B) is from 3:1 to 1:7. 8 . A composition according to claim 7 , wherein the molar ratio of (A) to (B) is from 2:1 to 1:2. 9 . A composition according to claim 1 , wherein (C) is lactose. 10 . A composition according to claim 9 , wherein (C) is lactose monohydrate. 11 . A composition according to claim 1 that further comprises magnesium stearate.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for disorders of the respiratory system · CPC title
- A61K31/4704Primary
2-Quinolinones, e.g. carbostyril · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
- A61K31/402Primary
1-aryl substituted, e.g. piretanide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016101097A1 cover?
- A medicament comprising, separately or together (A) glycopyrrolate; and (B) either a compound of formula I in free or salt or solvate form, wherein W, R x , R y , R 1 , R 2 , R 3 , R 4 , R 5 , R 8 and R 7 have the meanings as indicated in the specification, or a compound of formula II …
- Who is the assignee on this patent?
- Collingwood Stephen Paul, Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4704. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Apr 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).